Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23534988

DOI
10.1586/erp.13.18

Indexing Status
Subject indexing assigned by NLM

MeSH
Albumin-Bound Paclitaxel; Albumins /administration & dosage /economics /therapeutic use; Antineoplastic Agents, Phytogenic /administration & dosage /economics /therapeutic use; Breast Neoplasms /drug therapy /economics /pathology; Castor Oil /analogs & derivatives /chemistry; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Markov Chains; Models, Economic; Nanoparticles; Neoplasm Metastasis; Paclitaxel /administration & dosage /economics /therapeutic use; Quality-Adjusted Life Years; Spain; Time Factors; Treatment Outcome

AccessionNumber
22013048893

Date bibliographic record published
03/12/2013